How should hyperaldosteronism be treated in a pregnant patient?

Treatment of Hyperaldosteronism in Pregnancy

Pregnant women with hyperaldosteronism should be treated medically with amiloride as the first-line agent, avoiding spironolactone due to its anti-androgenic effects, and surgery should only be considered in early pregnancy for unilateral disease, as adrenalectomy during pregnancy does not improve outcomes over medical management alone 1.

Diagnostic Considerations

Diagnosing primary aldosteronism (PA) during pregnancy is challenging because:

• Normal pregnancy physiologically increases aldosterone and renin levels
• Progesterone has antagonistic effects on aldosterone
• Many cases present as normokalemic hypertension 2

Any treatment-resistant hypertension in pregnancy warrants evaluation for PA 3. Ideally, fertile women with hypertension should be screened for PA before pregnancy to allow for optimal management planning 1.

Medical Management Algorithm

First-Line Treatment: Amiloride

• Dosing: 10-15 mg daily effectively controls blood pressure and reverses hypokalemia 3
• Safety profile: Multiple case reports demonstrate safe use throughout pregnancy with normal fetal development and healthy deliveries 3
• Mechanism: Epithelial sodium channel (ENaC) inhibitor that blocks aldosterone's effects without anti-androgenic properties

Medications to AVOID:

• Spironolactone: Contraindicated due to anti-androgenic effects that can cause feminization of male fetuses 3, 2
• Eplerenone/Esaxerenone: Limited safety data, though one case report showed successful use of esaxerenone 4
• ACE inhibitors and ARBs: Teratogenic and contraindicated in pregnancy 5

Adjunctive Antihypertensives

When amiloride alone is insufficient, add pregnancy-safe agents:

• Nifedipine (calcium channel blocker)
• Methyldopa
• Labetalol
• Hydralazine 3

Surgical Management

Adrenalectomy during pregnancy should generally be avoided 1. Key evidence:

• Systematic review showed that adrenalectomy during pregnancy did not improve maternal or fetal outcomes compared to medical treatment alone 1
• Surgery may be considered only in early pregnancy for unilateral disease if medical management fails
• Optimal approach: Diagnose and surgically treat unilateral PA before pregnancy or defer surgery until postpartum 1

Outcomes and Complications

Maternal and Fetal Risks:

• Complications occur in 62.2% of pregnant women with non-familial PA 1
• Increased risk of:
  • Preeclampsia/superimposed preeclampsia 6, 4
  • Intrauterine growth restriction 6
  • Preterm delivery 6
  • Resistant hypertension requiring multiple agents

Prognostic Factors:

• Unilateral PA surgically treated before or after pregnancy has better outcomes than treatment during pregnancy 1
• Familial hyperaldosteronism type I has lower complication rates (18.5%) compared to sporadic forms 1

Clinical Pitfalls to Avoid

1. Don't dismiss resistant hypertension in pregnancy as "just preeclampsia" - always consider secondary causes including PA 3

2. Don't use spironolactone - despite being standard PA treatment outside pregnancy, the anti-androgenic effects make it absolutely contraindicated 3, 2

3. Don't assume surgery is always better - the evidence clearly shows medical management is safer during pregnancy 1

4. Don't delay diagnosis - early identification allows for better counseling and management planning 1

Postpartum Management

• Amiloride can be discontinued after delivery if blood pressure normalizes 4
• Reassess for definitive treatment (surgery for unilateral disease, long-term MRA for bilateral disease)
• Consider screening before subsequent pregnancies 1